Group 1 - The core point of the article is that Jianmin Group has received approval from the National Medical Products Administration for its furosemide oral solution to be marketed [2] Group 2 - The announcement was made on the evening of September 1 [2] - The approval signifies a significant milestone for the company's product development and market entry [2]

证券代码：600976 证券简称：健民集团 公告编号：2025-033 健民药业集团股份有限公司 关于呋塞米口服溶液获批上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，健民药业集团股份有限公司（以下简称"公司"）从国家药品监督管 理局网站获悉，公司研发的呋塞米口服溶液获批上市。现将相关情况公告如下： 一、药品获批上市的主要内容 药物名称：呋塞米口服溶液 剂型：口服溶液剂 药品批准文号：国药准字 H20255196 药品批准文号有效期：至 2030 年 08 月 25 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 申请事项：药品注册（境内生产） 二、药品研发及相关情况 规格：60ml:0.6g 药物名称：呋塞米口服溶液 注册分类：化药 3 类 包装规格：1 瓶/盒 处方药/非处方药：处方药 上市许可持有人：健民药业集团股份 ...

Core Viewpoint - The approval of the oral solution of Furosemide by Jianmin Group represents a significant advancement in the treatment options for conditions such as heart failure, liver cirrhosis, and kidney-related edema, as well as hypertension [1] Company Summary - Jianmin Group has received approval from the National Medical Products Administration for its Furosemide oral solution [1] - The oral solution is a high-efficiency diuretic, which is more suitable for children compared to traditional tablet and injection forms, enhancing medication safety and adherence [1] - The developed product has the same active ingredients, excipients, dosage form, specifications, indications, administration routes, and dosages as the reference original preparation, indicating its clinical application value [1] Industry Summary - The introduction of the oral solution will provide more treatment options in the relevant disease areas, potentially impacting the market for diuretics and related medications [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for its oral solution of Furosemide, a potent diuretic used for treating edema related to heart failure, liver cirrhosis, and kidney diseases, as well as hypertension [1] Group 1 - The oral solution formulation is more suitable for children compared to traditional tablet and injection forms, enhancing medication safety and adherence [1]

Market Overview - The Shanghai Composite Index closed at 3857.93 points, above the annual line, with a change of 0.37% [1] - The total trading volume of A-shares reached 28,301.97 billion yuan [1] Stocks Breaking Annual Line - A total of 22 A-shares have surpassed the annual line today, with notable stocks including Guoan Co., Transsion Holdings, and ST Huawen, showing divergence rates of 6.70%, 5.14%, and 4.43% respectively [1] - Stocks with smaller divergence rates that just crossed the annual line include Changjiang Electric, ST Zhongzhuang, and Laobaigan Liquor [1] Top Divergence Rates - The top three stocks with the highest divergence rates are: - Guoan Co. (10.07% increase, 6.70% divergence) - Transsion Holdings (7.17% increase, 5.14% divergence) - ST Huawen (4.86% increase, 4.43% divergence) [1] Additional Stock Performance - Other notable stocks include: - Shenyang Machine Tool (4.49% increase, 3.75% divergence) - Shangong Shenbei (4.20% increase, 3.64% divergence) - ST Boda (4.10% increase, 3.48% divergence) [1]

Group 1 - The core viewpoint of the news is that Jianmin Group (600976) has shown a slight increase in stock price, but the company is experiencing a decline in revenue and net profit according to its latest financial report [1][3] - As of August 25, 2025, Jianmin Group's stock closed at 41.52 yuan, with a trading volume of 54,600 lots and a transaction amount of 226 million yuan [1] - The company's latest interim performance report shows total operating revenue of 1.805 billion yuan, a year-on-year decrease of 10.20%, and a net profit attributable to shareholders of 221 million yuan, down 7.83% year-on-year [1] Group 2 - The company has a current ratio of 1.561, a quick ratio of 1.385, and a debt-to-asset ratio of 41.44% [1] - Jianmin Pharmaceutical Group Co., Ltd. was established in 1993 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 153.3986 million yuan [1] - The company has made investments in 30 enterprises and has participated in 5,000 bidding projects, holding 526 trademark registrations and 242 patents [2]

Core Viewpoint - Jianmin Group reported a net profit of 221 million yuan for H1 2025, representing a year-on-year decline of 7.83% while experiencing rapid growth in industrial revenue and expected volume increase in pediatric new drugs [1] Group 1: Financial Performance - The net profit for H1 2025 was 221 million yuan, down 7.83% year-on-year [1] - R&D expenses reached 52.97 million yuan in H1 2025, an increase of 30.89% year-on-year [1] Group 2: Business Strategy - The company adheres to a dual-brand strategy with "Longmu" for pediatric drugs and "Jianmin" for chronic disease and family essential medications, focusing on multiple core products [1] - The OTC product line is expected to maintain rapid revenue growth due to brand strategy upgrades and accelerated product launches [1] Group 3: Product Development - The company is enhancing its product portfolio in the digestive field, with two products, Tongjiao Granules and Zhizhu Tongbian Granules, entering Phase III clinical trials [1] - The company is recognized as a leading pediatric drug enterprise in China, with a clear release schedule for innovative Chinese medicine products in hospitals [1]

Core Viewpoint - The recent financial report of Jianmin Group shows a decline in revenue and net profit for the first half of 2025, indicating challenges in the pharmaceutical market and increased operational costs [1][3]. Financial Performance - Total revenue for the first half of 2025 was 1.805 billion yuan, a decrease of 10.2% year-on-year [1]. - Net profit attributable to shareholders was 221 million yuan, down 7.83% year-on-year [1]. - In Q2 2025, total revenue was 913 million yuan, a decline of 12.21% year-on-year, with net profit of 110 million yuan, down 21.01% year-on-year [1]. - The gross margin improved to 59.44%, an increase of 38.26% year-on-year, while the net margin was 12.32%, up 2.73% year-on-year [1]. - The total of selling, administrative, and financial expenses reached 869 million yuan, accounting for 48.17% of total revenue, an increase of 34.66% year-on-year [1]. Key Financial Ratios - Earnings per share (EPS) decreased to 1.46 yuan, down 6.41% year-on-year [1]. - The company's net asset per share increased to 16.41 yuan, up 9.12% year-on-year [1]. - Operating cash flow per share remained stable at 0.36 yuan, with a slight increase of 0.84% year-on-year [1]. Changes in Financial Items - Accounts receivable decreased by 14.4% to 907 million yuan, while cash and cash equivalents fell by 8.36% to 171 million yuan [3]. - Short-term borrowings decreased significantly by 60.96% due to repayments by commercial subsidiaries [3]. - The company experienced a substantial increase in financial expenses, up 351.65%, attributed to changes in accounting for discounted bills [3]. Business Model and Strategy - The company relies heavily on marketing-driven performance, with a return on invested capital (ROIC) of 15.14% for the previous year, indicating strong capital returns [4]. - The company is focusing on optimizing its marketing assessment system and enhancing digital capabilities to improve sales performance [7]. Market Outlook - Analysts expect the company's performance in 2025 to reach 448 million yuan, with an average EPS forecast of 2.92 yuan [5]. - The company has seen a positive trend in sales of certain products, such as Longmu Bone Strengthening Granules and Jianpi Shengxue Granules, despite market challenges [7].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is expected to experience rapid growth in industrial revenue in the first half of 2025, with new pediatric drugs anticipated to gain market traction [5] - The company's revenue for the first half of 2025 was 1.805 billion yuan, a year-on-year decrease of 10.20%, while the net profit attributable to the parent company was 221 million yuan, down 7.83% [7] - The pharmaceutical industrial segment showed strong performance with a revenue increase of 23.07%, while the pharmaceutical commercial segment saw a decline of 37.82% due to restructuring efforts [7] - The company is focusing on a dual-brand strategy with "Longmu" for pediatric drugs and "Jianmin" for chronic disease and family medicine, which is expected to drive growth in the OTC product line [7] - The company is accelerating the commercialization of innovative traditional Chinese medicine, with significant new product launches and increased R&D investment [7] Summary by Sections Financial Performance - For 2023, the projected revenue is 4.213 billion yuan, with a year-on-year growth rate of 15.72%. However, a decline is expected in 2024 and 2025, with revenues of 3.505 billion yuan and 3.205 billion yuan respectively [6] - The net profit attributable to the parent company is forecasted to be 521 million yuan in 2023, with a significant drop in 2024 to 362 million yuan, followed by a recovery to 448 million yuan in 2025 [6] - The earnings per share (EPS) is expected to be 3.40 yuan in 2023, decreasing to 2.36 yuan in 2024, and then recovering to 2.92 yuan in 2025 [6] Business Strategy - The company is implementing a brand strategy that focuses on enhancing the market share and influence of its pediatric drug line and OTC products [7] - The innovative traditional Chinese medicine products are expected to gain traction, with new approvals and increased market coverage [7] Future Outlook - The company anticipates net profits of 448 million yuan in 2025, 514 million yuan in 2026, and 586 million yuan in 2027, with respective growth rates of 24%, 15%, and 14% [7] - The current stock price corresponds to a price-to-earnings (P/E) ratio of 14X for 2025, indicating a favorable valuation for potential investors [7]

Group 1 - The core point of the article is that Jianmin Group reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [2] - The company's operating revenue for the first half of 2025 was 1,804,599,192.51 yuan, representing a year-on-year decrease of 10.20% [2] - The net profit attributable to shareholders of the listed company was 220,625,625.18 yuan, showing a year-on-year decline of 7.83% [2]